A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and
safety of AL002 in participants with Early Alzheimer's Disease.